Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO

Biotech entrepreneur, company founder, tireless patient advocate, and U.S. Navy combat veteran will guide the life science industry in its mission to feed, fuel and heal the world

John Crowley headshot

December 5, 2023 | The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and industry trailblazer who has served as BIO’s CEO on an interim basis for the past year.

Crowley is best known for his role as an entrepreneur in the biotechnology industry following the 1998 diagnosis of his two youngest children with Pompe disease, a rare and often fatal neuromuscular disorder. His children’s diagnosis inspired him to co-found a biotech company to develop a treatment that he credits with ultimately saving his children’s lives. The Crowley family journey was depicted in the major motion picture “Extraordinary Measures” starring Harrison Ford, Brendan Fraser, and Keri Russell. In 2005, Crowley went on to help found Amicus Therapeutics, a now 500+ person global biotechnology company, where he served as Chairman and CEO from 2005-2022 and is presently the company’s Executive Chairman. He will remain in that role until he transitions to BIO.

Crowley’s decades of biotech experience and deep passion for the field will be pivotal in helping BIO reimagine how the world thinks about drug development. He is a strong supporter of policies that empower innovation, enable entrepreneurship, and put patients first. Crowley also has been a leading voice globally for universal access to medicines, especially for children, people living with rare and other life-threatening diseases, and those with disabilities. As the father of two children living with a rare disease, he brings a unique understanding of the challenges patients, their families, and caregivers face, as well as the transformative opportunities that biotechnology presents to alleviate human suffering. This has been his life’s mission.

“In every role I’ve held in my life—biotech founder, U.S. Navy intelligence officer, husband and most importantly, father and grandfather—I have asked myself, ‘What is the mission?’” said Crowley. “When I founded our first company, the mission was to create a therapy to save our children and others from Pompe disease. Today, there are untold millions of children and adults waiting for ‘their’ cures and treatments – as well as literally billions of people who need agricultural advances and climate solutions that biotechnologies can provide. The mission of BIO is the mission of our members: cure patients, protect our climate, and nourish humanity. I am humbled and honored to lead BIO as we enter this golden age of medicine and the coming age of biotechnology. And I am eager to continue working alongside our members and dedicated BIO leadership and staff to drive this mission forward.”

BIO represents roughly 1,000 members, including members working to deliver new animal health, plant, microbial and biobased products of biotechnology to support food security and address climate change. “While my life’s work has centered on creating life-changing and lifesaving medical therapies, I am excited about advancing these critical issues in agriculture and the environment for our society, as well as growing the membership base that drives our mission,” said Crowley, a longtime BIO board member and current BIO Vice Chair. “BIO’s presence at this year’s United Nations Climate Change Conference – COP28 – will give us an exceptional platform to showcase our member companies’ great work.”     

“Having worked alongside John for many years, I can attest to his unwavering commitment to patients. He possesses a lifelong dedication to service, whether fighting for his country, wisely negotiating on behalf of our companies in Congress, or advocating in hospitals on behalf of his children and patients with rare disease,” said BIO Board Chair Dr. Ted W. Love. “After an exhaustive search for the right leader, we were thrilled that John decided to take on this influential role. We can’t thank Rachel King enough for her willingness to come out of retirement to lead BIO during this transition. Her dedication has made it possible for us to find the right leader for the job, and we are delighted she will ensure a smooth transition until John assumes the role in early 2024.”  

“I’ve had the pleasure of working with John for many years as a Board member, and for the past year as part of BIO’s leadership team,” says Rachel King, co-founder and former CEO of GlycoMimetics, Inc., who has been serving as BIO’s President and CEO since October 2022. “There couldn’t be a better person to lead our members in 2024 and beyond, and I look forward to continuing to work together to advance this incredibly important industry in its pursuit to change people’s lives for the better.”

King will continue to serve in her current role until March 4, when Crowley transitions into his new position at BIO.

##

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the  BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.  Good Day BIO  is the only daily newsletter at the intersection of biotech, politics and policy.  Subscribe here.

Why PDUFA Reauthorization Matters for Georgia’s Patients and Economy

October 30, 2026
For Georgians living with serious and rare diseases, how quickly and predictably a new treatment moves through U.S. Food and Drug Administration (FDA) review can make a real difference. That predictability also matters to the researchers and businesses that make up Georgia’s growing life sciences sector. Both depend in large part on the Prescription Drug User Fee Act (PDUFA), a longstanding bipartisan program that Congress needs to reauthorize by 2027. How PDUFA Works Since 1992, PDUFA has allowed the FDA to collect user fees from biopharmaceutical companies to supplement the agency’s resources for reviewing new medicines. In exchange, the FDA commits to clear, predictable review timelines. The agency’s standards for safety and efficacy remain unchanged. By providing additional resources and establishing clear performance goals, PDUFA helps ensure patients can access new treatments in a more timely and predictable manner. The result of PDUFA have been significant. Before PDUFA, FDA reviews often took more than two years. Today, the median review time is 10 months for standard applications and 8 months for priority applications. In 2025, nearly 70% of new medicines were approved in the U.S. before any other country. What’s at Stake in 2027 Congress reauthorizes PDUFA every five years. The current agreement, PDUFA VII, expires September 30, 2027. Timely reauthorization is critical to maintaining the FDA’s review capacity, preserving regulatory predictability, and ensuring patients continue to benefit from medical innovation. Georgia stakeholders recently came together to talk through what that means here at home. On October 28, Georgia Life Sciences, the MTS Sickle Cell Foundation, and Georgia First hosted “PDUFA: How Medicines Reach People,” a lunch-and-learn at Brookhaven City Centre. Patient advocates, congressional staff, and business and academic leaders heard from Nick Magallanes of Todd Strategy Group, Natalie Crawford of Georgia First, Maria Thacker-Goethe of Georgia Life Sciences, and Mapillar Dahn of the MTS Sickle Cell Foundation. What We Heard At the event, speakers came at PDUFA from different angles, but the common thread was how the program affects Georgians. Mapillar Dahn of the MTS Sickle Cell Foundation stressed that patients need to remain at the center of conversations. As a mother of three daughters with Sickle Cell Disease, Mapillar stressed that she wants the FDA to have what it needs to carry out a thorough review without unnecessary delays. The confidence families place in a treatment depends in part on confidence in that process. Natalie Crawford with Georgia First and Mended Hearts spoke about the need for a fully resourced FDA so that Georgia patients have access to innovative treatments and also for a healthy Georgia economy. Additionally, Maria Thacker-Goethe spoke to what PDUFA reauthorization means for Georgia’s booming life sciences sector. She warned that without PDUFA reauthorization, research across the board will be stifled – ranging from devastating impacts to small startups to significant delays in investments and research. Part of a National Conversation As Congress prepares for the 2027 reauthorization, conversations like these help bring together patients, advocates, and community leaders to highlight the real-world importance of the program. Decisions made in this reauthorization cycle will shape FDA resources and review timelines nationwide. By reauthorizing PDUFA on time, Congress can make sure the FDA can keep reviewing new medicines efficiently and patients in Georgia and across the country can get the treatments they need. 

Georgia’s MedTech Momentum: Building on Growth and Strengthening Our Innovation Ecosystem

October 29, 2026
New Hypepotamus feature explores Georgia’s growing MedTech sector and opportunities to strengthen startup development, commercialization, and long-term industry growth Georgia’s life sciences industry is experiencing significant growth, fueled by major investments, expanding research capabilities, and an increasingly connected innovation ecosystem. From biotechnology and medical devices to diagnostics and digital health, the state continues to demonstrate its potential as a destination for life sciences innovation. As Georgia builds on that momentum, an important opportunity is emerging: ensuring that the startups and technologies developed here have the resources and support to grow, scale, and remain in the state. A new Hypepotamus feature, “Atlanta’s MedTech Momentum Faces a Test: Can Startups Stay and Scale?” , by Maija Ehlinger, explores this next phase of ecosystem development. Featuring perspectives from entrepreneurs, investors, and industry leaders, including Georgia Life Sciences President & CEO Maria Thacker Goethe, the article examines how Georgia can build on its existing strengths while addressing challenges facing emerging companies. A Strong Foundation for Continued Growth Georgia has made substantial progress in establishing itself as a competitive life sciences hub. Recent major investment announcements, including UCB’s planned $2 billion biologics manufacturing facility in Gwinnett County and Shriners Children’s planned investment of more than $153 million in a research institute at Science Square, reflect continued confidence in the state's capabilities and potential. The state also benefits from a strong network of research universities, healthcare systems, entrepreneurial support organizations, and innovative companies developing technologies that have the potential to improve patient care and advance medical discovery. Programs and facilities such as Georgia Tech's ATDC, BioSpark Labs, and other regional innovation resources provide important support for emerging companies, helping entrepreneurs move promising ideas toward commercial application. These assets represent a strong foundation for future growth. Addressing the Needs of a Maturing Ecosystem While Georgia's industry continues to advance, emerging MedTech and biotechnology companies face challenges that extend well beyond the state. A changing investment environment, increasingly complex commercialization pathways, and demand for specialized infrastructure are reshaping how early-stage companies develop and grow. The Hypepotamus article highlights some of these pressures, including the recent closure of Portal Innovations' Atlanta location and the challenges startups encounter in securing affordable laboratory space, early-stage capital, and industry connections. These developments underscore the importance of strengthening the support systems that enable innovation. They also reflect a broader opportunity for Georgia to build on its progress and ensure that companies at every stage of development can access the resources they need. “Our biggest opportunity is to become as good at growing and retaining life sciences companies as we are at attracting major investments,” said Thacker Goethe in the article. A Roadmap for Georgia’s Next Chapter This focus on growing and retaining innovative companies is central to Georgia Life Sciences' 10-year strategic roadmap , which outlines priorities to strengthen the state's life sciences ecosystem and long-term competitiveness. The roadmap recognizes that continued industry growth requires a coordinated approach to commercialization, access to capital, specialized infrastructure, workforce development, and partnerships across academia, industry, healthcare, and government. For early-stage companies, those connections are especially important. Access to research facilities, clinical partners, experienced mentors, investors, and manufacturing resources can make the difference between a promising discovery and a successful commercial enterprise. Through its industry councils, strategic partnerships, and ecosystem initiatives, Georgia Life Sciences is working to help strengthen these connections and support the development of an environment where companies can succeed at every stage of growth. Turning Momentum into Long-Term Opportunity Georgia's life sciences story is one of substantial progress and considerable opportunity. The next chapter will require building on that success with the same intentionality that has helped attract major industry investments and expand the state's research and innovation capabilities. That means continuing to support companies choosing Georgia for major investments while also strengthening the pathways that allow homegrown businesses to develop, commercialize, and scale here. The goal is not simply to attract life sciences innovation to Georgia, but to ensure Georgia is a place where innovation can take root, grow, and thrive. The Hypepotamus feature offers a timely perspective on the opportunities ahead and the importance of continued collaboration across Georgia's life sciences community.  Read the Full Hypepotamus Article

Georgia Bioscience Industry Reaches 42,605 Jobs, Contributing $1.5 Billion in Venture Capital Investment

October 28, 2026
New national report highlights Georgia’s growing bioscience workforce, research enterprise, and investment activity October 28— Georgia’s bioscience industry continues to expand its economic footprint, supporting 42,605 jobs across 4,281 business establishments statewide in 2025, according to a new report examining the economic impact of the U.S. bioscience industry. The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions, published by the Biotechnology Innovation Organization (BIO), the Council of State Bioscience Associations, and TEConomy Partners, provides a comprehensive assessment of the bioscience industry’s contributions to employment, wages, business growth, university research and development, and access to capital across all 50 states, Washington, D.C., and Puerto Rico. Georgia’s bioscience employment grew 7.6% between 2021 and 2025, slightly outpacing national growth. The state recorded employment gains across all five major bioscience industry subsectors, demonstrating the breadth of its life sciences economy. “Georgia’s bioscience industry is an important contributor to our state’s economic competitiveness, creating high-quality jobs and advancing research and innovation,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences. “These findings underscore the opportunity to build on Georgia’s strengths by strengthening connections among research institutions, industry, investors, and workforce partners to help more life sciences companies innovate and grow here.” Georgia’s Bioscience Industry: Key Findings The report highlights several indicators of Georgia’s bioscience industry strength: 42,605 jobs: Georgia’s bioscience industry employed more than 42,000 people in 2025, with employment growing 7.6% from 2021 to 2025. 4,281 business establishments: Bioscience companies and related businesses operate across the state, contributing to Georgia’s diverse economic base. $112,712 in average annual wages: Bioscience industry wages exceeded Georgia’s private-sector average by 52%, highlighting the sector’s contribution to high-value employment. $2.0 billion in university bioscience research: Georgia universities conducted $2.0 billion in bioscience-related research and development in fiscal year 2024. $789.5 million in NIH funding: Georgia institutions received $789.5 million in National Institutes of Health funding in fiscal year 2025. $1.5 billion in venture capital investment: Georgia bioscience companies attracted $1.5 billion in venture capital from 2021 through 2025. Georgia’s bioscience distribution subsector, the state’s largest, expanded employment by 10.3% during the period. Agricultural feedstock and industrial biosciences recorded the fastest percentage growth, reflecting the breadth of activity across the state’s bioscience economy. National Industry Impact Nationally, the U.S. bioscience industry generated $3.19 trillion in total economic output and directly employed 2.31 million Americans across more than 156,000 business establishments. The report examines the industry's economic footprint and the factors that support its continued growth, including research investment, workforce development, and access to capital. Building on Georgia’s Life Sciences Momentum The findings highlight Georgia’s substantial research enterprise, established industry base, and ability to attract investment. Continued growth will depend on strengthening the connections that help translate scientific discoveries into commercial opportunities, expand access to capital, develop a skilled workforce, and provide the infrastructure companies need to scale. Georgia Life Sciences works to advance the state’s life sciences ecosystem through policy and advocacy, workforce development, industry convening, and strategic collaboration. Its statewide roadmap, Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector, outlines a long-term vision for positioning Georgia as a leading scale-up manufacturing hub in the Southeast. “Georgia has significant assets across research, manufacturing, workforce, and logistics,” Goethe said. “By coordinating these strengths and addressing the gaps that can limit company growth, we can create more opportunities for innovation, investment, and long-term economic impact across the state.” Read the Report The full report, The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions, and Georgia’s state-specific profile are available from the Biotechnology Innovation Organization. Explore the national report and findings Download Georgia’s state profile (PDF)
MORE POSTS